Indian Journal of Sleep Medicine

Register      Login

VOLUME 9 , ISSUE 3 ( July-September, 2014 ) > List of Articles

ORIGINAL ARTICLE

Neuropathic pain and sleep disturbances with special reference to patients with postherpetic neuralgia

Namita V. Nasare, Pramod K. Medirattaa, Basu D. Banerjee, Pravin S. Deshmukh, Ashok K. Saxena, Sambit N. Bhattacharya, Rafat S. Ahmed

Keywords : Sleep scores, Global perceived effect, Tramadol, CYP2D6, Postherpetic neuralgia

Citation Information : Nasare NV, Medirattaa PK, Banerjee BD, Deshmukh PS, Saxena AK, Bhattacharya SN, Ahmed RS. Neuropathic pain and sleep disturbances with special reference to patients with postherpetic neuralgia. Indian Sleep Med 2014; 9 (3):119-127.

DOI: 10.5958/0974-0155.2014.01113.9

License: CC BY-SA 4.0

Published Online: 00-09-2014

Copyright Statement:  Copyright © 2014; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Objective: The impacts of postherpetic neuralgia (PHN) on patients’ quality of sleep and global perceived effects (GPEs) are poorly documented. Our main aim of the study was to determine the improvement of sleep and GPE after 4 weeks of tramadol (50–200 mg) treatment with rescue analgesia in the form of topical cream containing 3.33% doxepin and 0.05% capsaicin in patients with PHN in relationship with CYP2D6 polymorphism. Methods: This study mainly comprised 246 patients with PHN including 123 nonresponders and 123 responders undergoing tramadol treatment. The sleep interference was assessed on 0–10 scale using Daily Sleep Interference Scale. The subjects’ overall impression (global evaluation) of the study medication was recorded by subjects’ answering the question. All samples were analyzed for CYP2D6*4 and CYP2D6*10 polymorphism using polymerase chain reaction–restriction fragment length polymorphism method. Results: Clinically significant (p<0.001) results were obtained in both the groups when compared with baseline between the Numerical Rating Scale (NRS) sleep scores and GPE scores whereas no associations were found between NRS sleep scores and GPE scores when compared with CYP2D6*4 and *10 polymorphisms (p > 0.05). Conclusions: Treatment with tramadol 50–200 mg/day was found to be significantly associated with reduced sleep interference and improved GPEs of patients with PHN. CYP2D6 (*4 and *10) polymorphisms with respect to NRS sleep and GPE may not be a sleep and GPE predictor for patients with PHN.


PDF Share
  1. Gilden DH. Herpes zoster with post herpetic neuralgiapersisting pain and frustration. N Engl J Med 1994;330:932–4.
  2. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: A self-limited disease with severe impact. Neurology 1995;45:S52–3.
  3. Graff-Radford SB, Kames LD, Naliboff BD. Measure of psychological adjustment and perception of pain in post herpetic neuralgia and trigeminal neuralgia. Clin J Pain 1986;2:55–8.
  4. Drewes AM. Pain and sleep disturbance with special reference to fibromyalgia and rheumatoid arthritis. Rheumatology (Oxford) 1999;38:1035–8.
  5. Kundermann B, Spernal J, Huber MT, Krieg JC, Lautenbacher S. Sleep deprivation affects thermal pain thresholds but not somatosensory thresholds in healthy volunteers. Psychosom Med 2004;66:932–7.
  6. Onen SH, Alloui A, Gross A, Eschallier A, Dubray C. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. J Sleep Res 2001;10:35–42.
  7. Deardorff W. Chronic Pain and Insomnia: Breaking the Cycle, 2007. Available at: http://www.spine-health.com/ wellness/sleep/chronic-pain-and-insomnia-breaking-cycle (last accessed on December 19, 2013).
  8. Cohen MJM, Menefee LA, Doghramji K, Anderson WR, Frank ED. Sleep in chronic pain: Problems and treatments. Int Rev Psychiatry 2000;12:115–26.
  9. Raffa RB, Friderichs E. The basic science aspect of tramadol hydrochloride. Pain Rev 1996;3:249–71.
  10. Dayer P, Desmeules J, Collart L. [Pharmacology of tramadol.] [Article in French] Drugs 1997;53:18–27.
  11. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879–923.
  12. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237–51.
  13. Finnerup NB, Jensen TS. Mechanisms of disease: Mechanism-based classification of neuropathic pain-a critical analysis. Nat Clin Pract Neurol 2006;2:107–15.
  14. Baron R. Mechanisms of disease: neuropathic pain: A clinical perspective. Nat Clin Pract Neurol 2006;2:95–106.
  15. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004;39:342–8.
  16. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389–400.
  17. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842–6.
  18. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000;14:65–70.
  19. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250–7.
  20. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: A randomized, double-blind, placebo-controlled trial. Pain 2003;104:323–31.
  21. Saxena AK, Nasare NV, Jain S, Dhakate G, Ahmed RS, Bhattacharya SN, et al. A randomized, prospective study of efficacy and safety of oral tramadol in the management of post herpetic neuralgia in patients from north India. Pain Pract 2013;13:264–75.
  22. Nasare NV, Banerjee BD, Deshmukh PS, Mediratta PK, Saxena AK, Ahmed RS, et al. CYP2D6*2 polymorphism as predictor of failed outpatient tramadol therapy in post herpetic neuralgia patients. Am J Ther [Epub ahead of print] 2013 Apr 5.
  23. Nasare NV, Deshmukh PS, Banerjee BD, Mediratta PK, Ahmed RS, Saxena AK, et al. CYP2D6*4 polymorphism in tramadol treatment and its clinical impact in patients of post herpetic neuralgia. Personalized Med 2012;9:371–85.
  24. Follin SL, Charland SL. Acute pain management: Operative or medical procedures and trauma. Ann Pharmacother 1997;31:1068–76.
  25. Lehmann K, Kratzenberg U, Schroeder-Bark B, Horrichs- Haermeyer G. Postoperative patient-controlled analgesia with tramadol: Analgesic efficacy and minimum effective concentration. Clin J Pain 1990;6:212–20.
  26. O'Connor AB. Neuropathic pain: Quality of life impact, costs and cost effectiveness of therapy. Pharmacogenomics 2009;27:95–112.
  27. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23–37.
  28. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442– 73.
  29. Poulsen L, Arendt-Nielsen L, Brøsen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60:636–44.
  30. Stamer UM, Lehnen K, Höthker F, Bayerer B, Wolf S, Hoeft A, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003;105:231–8.
  31. Hartrick CT, Kovan JP, Shapiro S. The numeric rating scale for clinical pain measurement: A ratio measure? Pain Pract 2003;3:310–6.
  32. Vernon MK, Brandenburg NA, Alvir JM, Griesing T, Revicki DA. Reliability, Validity, and Responsiveness of the Daily Sleep Interference Scale among Diabetic Peripheral Neuropathy and Postherpetic Neuralgia Patients. J Pain Symptom Manage 2008;36:58–68.
  33. Kamper SJ, Ostelo RW, Knol DL, Maher CG, de Vet HC, Hancock MJ. Global perceived effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. J Clin Epidemiol 2010;63:760– 6.
  34. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmöller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008;28:78–83.
  35. Nageswararao D, Manjula G, Sailaja K, Raghunadharao S, Vishnupriya R. Association of CYP2D6*4 polymorphism with acute leukemia. J Cell Tissue Res 2010;10:2201–5.
  36. Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: A randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manag 2004; 28:59–71.
  37. Nicholson B. Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract 2009;9:71–81.
  38. McQuay HJ, Tramèr M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217–27.
  39. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: A quantitative systematic review. J Pain Symptom Manage 2000;20:449–58.
  40. Watson CP. A new treatment for postherpetic neuralgia. N Engl J Med 2000;23:1563–5.
  41. McQuay HJ, Carroll D, Jadad AR, Glynn CJ, Jack T, Moore RA, et al. Dextromethorphan for the treatment of neuropathic pain: A double-blind randomized controlled crossover trial with integral n-of-1 design. Pain 1994;59:127–33.
  42. McCleane GJ. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomised, double-blind, placebo controlled trial. Pain 1999;83:105–7.
  43. Wallace MS, Magnuson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: A doubleblind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000;25:459–67.
  44. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. New Engl J Med 2003;348:1223–32.
  45. Gimbel JS, Richards P, Portenoy RK. Controlled release oxycodone for pain in diabetic neuropathy. A randomized controlled trial. Neurology 2003;60:927–34.
  46. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology 2007;68:1178–82.
  47. Atkinson JH, Slatter MA, Patterson TL, Grant I, Garfin SR. Prevalence, onset, and risk of psychiatric disorders in men with chronic low back pain a controlled study. Pain 1991;45:111–21.
  48. Norrbrink C, Lundeberg T. Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial. Clin J Pain 2009;25:177–84.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.